Creative Biolabs Expands Antibody Discovery Platform to Address Challenging Drug Targets

Creative Biolabs has shared that it is reorganizing its antibody discovery platform to better help research on tough drug targets, such as G-protein coupled receptors (GPCRs), ion channels, and proteins that have complicated changes after they are made (PTMs).

The update consolidates previously separate screening and characterization services into a more unified workflow, reflecting broader industry efforts to improve efficiency in early-stage drug discovery, where attrition rates remain high.

Refining the Discovery Process

At the center of the revised platform is an expanded Phage Display Library Construction capability. Compared with traditional animal-based immunization, synthetic libraries allow researchers to explore a wider diversity of antibody variants, potentially increasing the likelihood of identifying viable candidates while minimizing immunogenicity concerns.

To support more precise targeting, the platform incorporates multiple peptide library formats, each tailored to specific research needs:

• Linear libraries: Short peptide sequences (8–20 amino acids) used primarily for mapping linear epitopes
• Cyclic libraries: Structurally constrained peptides that improve stability, particularly useful in GPCR-related studies
• Mimotope libraries: Designed to replicate post-translational modifications, enabling targeted antibody development
• Constrained libraries: Backbone-stabilized peptides with enhanced resistance to enzymatic degradation
• Random libraries: Highly diverse collections that support discovery of novel binding interactions

These library systems are combined with de novo antibody sequencing and B-cell sorting to create a dual-validation workflow. This approach enables early cross-verification of candidates, with attention to properties such as stability and aggregation that influence downstream development.

Increasing Focus on PTM-Specific Targeting

The restructuring also reflects increasing demand for antibodies capable of distinguishing subtle molecular differences, particularly those introduced by post-translational modifications. This level of specificity is becoming increasingly important in areas such as oncology and neurodegenerative disease research.

The company claims that they have designed updated selection strategies to reduce non-specific binding and enhance the identification of antibodies that specifically recognize modified protein states. As part of this shift, the company has expanded its  PTM Specific Antibody Discovery capabilities incorporating selection strategies designed to reduce non-specific binding and improve identification of antibodies that selectively recognize modified protein states.

Integrating Discovery and Developability

A key feature of the updated platform is the closer integration of analytical and developability assessments with early discovery stages. Core components of the system include:

• Phage display screening: Enables identification of rare or difficult-to-target epitopes using synthetic libraries
• Hybridoma-based methods: Support in vivo maturation and generation of high-affinity monoclonal antibodies
• Analytical tools: Provide epitope mapping and sequencing data to support intellectual property and regulatory considerations
• Characterization assays: Evaluate immunogenicity and physicochemical properties to inform clinical viability

By incorporating these capabilities earlier in the workflow, the platform aligns with a broader shift in the contract research sector toward integrating risk assessment into initial discovery phases rather than later development.

For smaller biotechnology firms, such integrated approaches may offer access to advanced screening and analysis without the need for extensive in-house infrastructure, potentially improving efficiency and decision-making in early research.